港股異動丨開拓藥業漲近7%,就化妝品業務海外市場與塗麥科技簽訂運營合作協議
開拓藥業(9939.HK)盤初漲近7%,報1.24港元。消息面上,公司公佈,集團全資附屬公司蘇州開拓,與塗麥科技訂立品牌與銷售營運合作協議,內容有關公司化妝品,包括但不限於防脫、祛痘、美白等產品領域,在海外市場的銷售代理、品牌營運及市場推廣的業務合作。根據營運合作協議,集團及塗麥科技同意就化妝品在海外市場的品牌戰略營運達成共識。雙方基於各自的優勢與資源,建立合作關係。集團主要負責化妝品研發、生產及品質管控,確保產品符合相關法規和標準,並提供初期營運所需的免費樣品及專項推廣資源支持。塗麥科技主要負責化妝品營銷推廣業務,透過組建專業營運團隊,制定精準營銷方案並落地執行,以提升化妝品品牌市場銷量與知名度。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.